)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Shenzhen YHLO Biotech
Shenzhen YHLO Biotech (688575) investor relations material
Shenzhen YHLO Biotech Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary28 Oct, 2026
Executive summary
9M 2026 revenue rose 11.04% YoY to RMB 1.429bn; attributable net income increased 137.58% to RMB 143.55m, supported by higher reagent sales, improved margins and lower fair-value losses.
Q3 revenue grew 13.07% YoY and 10.33% QoQ to RMB 540.79m; attributable net income rose 114.97% YoY and 40.70% QoQ to RMB 73.42m.
Financial highlights
9M total profit was RMB 160.26m, up 148.55% YoY; Q3 total profit was RMB 85.29m, up 105.27%.
Adjusted for non-recurring items, attributable net income was RMB 152.02m for 9M, up 50.66%, and RMB 78.56m in Q3, up 54.45%.
9M operating cash flow reached RMB 381.21m, up 486.60% YoY, reflecting revenue growth, higher cash receipts and lower payments for goods and services.
Period-end total assets were RMB 4.338bn, up 1.15% from year-end 2025; parent-attributable equity was RMB 2.824bn, up 4.72%.
Outlook and guidance
Cardiovascular chemiluminescence reagent growth is viewed as a potential second growth driver; 9M sales rose 56.80% YoY and Q3 sales rose 70.36%.
Microfluidics cardiac-marker products entered a substantive commercialization phase after registration approvals for six reagent products and two instruments.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Shenzhen YHLO Biotech
- Net profit surged 166.97% YoY on 9.84% revenue growth and improved margins.688575
Q2 2026 - Net profit jumped 76.89% year-over-year, while revenue dipped and overseas sales rose 17.21%.688575Q1 2026
- Net profit plunged 92.26% on lower revenue and asset impairments, but R&D and overseas sales grew.688575H2 2025
- Q3 revenue up, profit down on asset losses; overseas business and innovation drive growth.688575Q3 2025
- Revenue and profit declined sharply, but overseas growth and R&D investment accelerated.688575H1 2025
- Non-COVID diagnostics and overseas business drove growth despite a sharp profit decline.688575Q3 2024
- Net profit rose 22.25% on strong non-COVID business despite a 10.69% revenue drop.688575H1 2024
- Net profit plunged 84.63% year-over-year despite strong overseas growth and product expansion.688575Q1 2025
- Adjusted net profit surged 31.16% on robust core business and margin improvement.688575Q4 2024
Next Shenzhen YHLO Biotech earnings date
H2 202623 Apr, 2027
Shenzhen YHLO Biotech
Next Shenzhen YHLO Biotech earnings date
H2 202623 Apr, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Shenzhen YHLO Biotech Co., Ltd., founded in 2008, is a Chinese company primarily focused on the research, development, manufacture, and sale of in-vitro diagnostic equipment and supporting reagents. The company's extensive product portfolio includes instruments and reagents based on chemiluminescence immunoassay, immunoblotting, enzyme-linked immunoassay, and immunofluorescence chromatography. These products are used in various medical fields, including autoimmunity, reproductive health, diabetes, and infectious diseases. The company is headquartered in Shenzhen, China, and its shares are listed on the Shanghai Stock Exchange.